Lung Cancer Trial, Recruiting NCT02688894 Sponsor: Samsung Medical Center Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT02688894
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their full informed consent before any study-related procedures begin
  • People who are 20 years of age or older
  • People who have been diagnosed with small cell lung cancer, confirmed through laboratory testing of tissue or cell samples
  • People whose physical functioning falls within a certain range, meaning they are able to carry out at least some daily activities (confirm with trial site for exact fitness level required)
  • People who are currently receiving or have previously received platinum-based chemotherapy as their first treatment for this cancer
  • People who either have stored tissue samples available for laboratory analysis, or who have agreed to have a biopsy taken for that purpose

Who may not be able to join:

  • People who have received more than two different chemotherapy treatment courses for small cell lung cancer
  • Women who are pregnant or breastfeeding; women who could become pregnant would need to agree to use an effective form of contraception
  • People who have a second type of cancer, with limited exceptions — those exceptions include certain treated skin cancers, successfully treated early-stage cervical cancer, or other solid cancers that were fully treated with no signs of return within the last two years (confirm with trial site for exact details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Se-Hoon Lee, MD, PhD, Samsung Medical Center

Phone: +82-10-4759-7640

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
29 April 2016
Est. completion
1 September 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Ratio of each molecular subtypes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov